Experimental analysis of complex quantitative genetic traits, such as essential hypertension, should be greatly facilitated by being able to manipulate the expression of a gene in living animals without altering the nudleotide sequence, chromosomal location, or regulatory elements of the gene. To explore this possibility, we have used targeted gene disruption and duplication to generate mice that are genetically identical [(129 x C57BL6)Fl] except for having one, two, or three functional copies of the gene coding for anglotensinen.
angiotensinogen levels -35% of normal (P < 0.0001), and the three-copy animals have levels -124% of normal (P < 0.004). Detailed information about regulatory sequences is not required for this.type of experiment; nor is it necessary to have DNA clones or targeting constructs that cover the whole of the target gene. Varying gene copy numbers by targeting consequently offers a promising approach to quantitative genetics.
Essential hypertension is characterized by elevated blood pressures without ascertained cause. Genetic and environmental factors are significant in its etiology, with the former being predominant (reviewed in ref. 1) . Its mode of inheritance is generally agreed to be polygenic, but specific genes have not been definitively identified. Indeed, different combinations of genetic variations may be operating in different individuals. One way of finding genes important in the etiology of a disease is the "candidate gene" approach. A candidate gene is chosen on the basis of nongenetic criteria, such as physiologic relevance, and genetic linkage studies are then carried out to look for cosegregation of polymorphic forms of the candidate gene and the disease. Using this approach, Jeunemaitre et al. (2) found evidence of genetic linkage between certain variants of the human angiotensinogen gene (AGI) and hypertension. [Angiotensinogen (AGT) is an essential precursor of a potent vasopressive octapeptide, angiotensin II.] The specific variants proved to be associated with an =20% higher level of AGT in the plasma, and the authors advanced the hypothesis that genetically determined elevated AGT levels might be predisposing for hypertension.
Our present experiments were initiated as the first step in testing this hypothesis in mice. Specifically, we have generated mice having genetically determined gradations in their steady-state plasma AGT levels, including levels close to those seen by Jeunemaitre et al. (2) Fig. 1A ) extending 5' of the transcriptional start of the gene was isolated from one of these clones. A 1.8-kb fragment extending 3' ofthe transcriptional stop was synthesized by PCR amplification using ES cell genomic DNA as the template with primers designed from the sequence of the mouse Agt gene (5). These two fiagments were then used to make the gap-repair targeting construct described below.
Cell Culture and Electroporation. Line E14TG2a ES cells (3) were used for targeting and were cultured on feeder cells as described (6) . Electroporation (7) The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Plasma AGT Levels. Plasma AGT levels were determined as angiotensin I equivalents by a radioimmunoassay for angiotensin I scaled down from the manufacturer's protocol (DuPont/NEN). Plasma samples (1 p1) had been incubated for 1 hr at 37TC with 4 p1 of a renin-containing kidney extract, prepared by homogenization of 14 adult mouse kidneys in 5 ml of 0.05 M sodium phosphate buffer (pH 7.4) followed by centrifugation for 1 hr at 100,000 x g (9) .
RESULTS AND DISCUSSION
Targeting Strategy for Gene Duplication. Fig. 1 illustrates with the mouse Agt gene how gap-repair targeting with an 0-type (insertional) targeting construct can create a complete tandem duplication of a gene. Targeting constructs to be used in this way must include two regions of homology, one from upstream (5') and a second from downstream (3') ofthe target gene locus. To maximize the probability that both copies of the tandemly duplicated gene will be fully functional, the 5' and 3' flanking regions of homology should extend far enough so that all known or suspected regulatory sequences can be expected to lie between their respective 5' and 3' ends. Spanning sufficient DNA to include all regulatory sequences is facilitated by noting that (i) the flanking sequences do not need to contain any coding sequences and (ii) they can be separated by a large gap because of the gap repair described Fig. 1 for their predicted sizes).
expected after successful gene duplication shows complete agreement (see Fig. 1C for expected sizes). The targeted ES cells have a normal Agt gene on one chromosome and a pair of tandemly duplicated genes on its homologue; the relative darknesses of the autoradiographic bands obtained with DNA from the targeted cells can consequently be used to check conclusions drawn from sizes. Thus the 3-kb Sac I band and the 13.5-kb HindIII band, which come only from the tandemly duplicated pair of Agt genes, should be-and indeed are-approximately half as dark as the 5-kb Sac I and 14-kb HindIII bands, which come from both the singleton Agt gene and the duplicated pair of genes. These data therefore establish that gap-repair gene targeting was achieved as illustrated in Fig. 1 and created Plasma AGT Levels Versus Gene Copy Number. Plasma samples were collected from three age-matched males and three age-matched females of the three Agt genotypes (1/0, 1/1, and 2/1) and AGT levels were determined. Three to six replicate measurements were made with every sample and were averaged. The average values were then expressed as percentages of the mean plasma AGT level for the six normal (1/1) animals to facilitate pooling of data. Note that these plasma AGT levels are steady-state levels, such as would normally be measured in human subjects; no attempt has been made to factor out the relative contributions to these values of production, utilization, clearance, etc.
The means of the individual percent AGT levels were then calculated for the six animals of each of the three genotypes. Fig. 3 displays these means, together with their standard deviations and the probabilities that the means forthe 1/0 and 2/1 animals differ significantly from that of the 1/1 animals. The data show that the 1/0 animals have =%35% of the level of normal 1/1 animals and that this difference is highly significant (P < 0.0001 by the two-sample t test). The 2/1 animals have -124% ofthe level of 1/1 animals, and again the difference is highly significant (P < 0.004). The conclusion is therefore clear-an increasing number offunctional copies of the Agt gene progressively and significantly increases the level of its product. We stress that the increased AGT level in the three-copy animals was achieved without altering the nucleotide sequences of either of the duplicated gene copies or their known regulatory elements and without changing their chromosomal location. We therefore expect that the duplicated Agt genes in these animals will have retained their normal patterns of tissue expression and regulation. This can be tested when 2/0 animals (see below) become available.
The extent of the changes in the steady-state plasma AGT level as the gene copy number varies requires comment. The one-copy animals have considerably less (35%) than half the plasma AGT levels ofthe two-copy animals. The level (124%) in the three-copy animals is also less than the value (150o%) expected from strict proportionality to gene dosage. This deviation from proportionality is not of great practical importance at this stage ofour investigations, since determining the effects on a downstream quantitative variable (in this case blood pressure) of increasing or decreasing the level of a specific gene product is not dependent on achieving some particular change in the level. In fact, the increase (24%) in plasma AGT levels in the three-copy animals is close to that (20%) observed by Jeunemaitre et al. (2) in their hypertensive patients. We thus anticipate being able to use our present animals to test the hypothesis that genetically determined elevations in plasma AGT levels in the range seen in humans are predisposing to hypertension.
Nevertheless, the reasons for deviation from proportionality are of interest. A likely explanation of the relatively reduced plasma AGT levels in the one-copy animals is that the amount of AGT synthesized from one gene is insufficient to maintain a half-normal steady-state plasma level in the face of the prevailing level of utilization and clearance. At least two factors could contribute to the nonlinear increase in AGT in the three-copy animals: utilization may be increased when AGT levels are above normal, and/or the pair of duplicated genes may not function at the same level as two singleton genes. The effectiveness of the duplicated Agt genes can be rigorously tested, when the relevant animals become available, by comparing the AGT levels in normal two-copy animals (1/1) with the levels in two-copy animals (designated 2/0) that are genetically identical except for having one chromosome with the Agt gene duplicated and one chromosome with the Agt gene disrupted.
General Comments. In assessing the relative effects of different genetic manipulations on a phenotype, particularly if the effects are subtle and only quantitative, it is highly advantageous to be able to keep all other genetic variables constant. In our current breeding system, this was achieved readily and rapidly by mating inbred strain 129-derived chimeras with inbred strain C57BL6 animals to obtain genetically uniform and vigorous (129 x C57BL6)F1 animals that differed only in their Agt genotypes. Other breeding schemes can achieve constant genetic backgrounds and an even greater span of gene copy numbers, although at the expense of hybrid vigor. For example, mating strain 129-derived male chimeras to strain 129 females and using their offspring for further breeding allows the production ofinbred 129 animals having 0, 1, 2, 3, or 4 copies of the Agt gene. The 2/0 animals required for the tests discussed above can be produced by mating strain 129 three-copy (2/1) and one-copy (1/0) animals.
An important consideration when exploring the effects of gene dosage changes on a complex quantitative phenotype is that the changes may have effects that are small or not detectable. Past studies of humans and other animals heterozygous (1/0) for a wide range of null mutations illustrate that frequently the phenotypic effects of halving the number of functional gene copies are subtle-possibly because the gene product is normally in large excess, or because compensatory changes occur in some related system. Indeed, much of the difficulty of deciphering the intricacies of complex quantitative genetic traits stems from such possibilities. Our scheme does not remove these possibilities. Rather it provides genetically uniform animals useful both for accurately assessing their magnitude and for determining their relevance under a variety ofconditions. For example, the achieved variations in level ofexpression may prove to have inconsequential effects under some environmental conditions but be important under others. And study of the compensations induced by a single genetic change is likely to indicate what other genetic systems merit study. The combined effects of changes in the levels of expression of two independent genes can then be studied.
Being able to genetically increase or decrease the expression of a gene, over ranges that are close to physiologic, without deliberately changing the chromosomal location or sequence of the gene and its regulatory elements appears therefore to offer a promising approach to analyzing complex quantitative genetic traits.
